Search for Clinical Trial Results

Epstein-Barr Virus Infections - 22 Studies Found
Status | Study |
Completed |
Study Name: EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients Condition: Epstein-Barr Virus Infections Date: 2009-08-20 |
Active, not recruiting |
Study Name: Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents Condition:
Date: 2015-01-07 |
Completed |
Study Name: Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) Condition: Epstein-Barr Virus Infections Date: 2003-04-08 Interventions: Biological: Intravenous injection of EBV specific CTLS The |
Recruiting |
Study Name: Mental Training for CFS Following EBV Infection in Adolescents Condition:
Interventions: Behavioral: Mental training |
Completed |
Study Name: Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations Condition: Epstein-Barr Virus Infections Date: 2003-10-07 |
Completed |
Study Name: Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts Condition: Epstein-Barr Virus Infections Date: 2003-04-11 Interventions: Biological: EBV specific T cells One injection of 2x10^7 cells/m2 from Day 45 post transplant. If EBV DN |
Active, not recruiting |
Study Name: A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma Condition:
Date: 2013-02-25 Interventions: Drug: MVA-EBNA1/LMP2 vaccine |
Completed |
Study Name: Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus Condition:
Date: 2000-06-24 |
Completed |
Study Name: Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). Condition:
Interventions: Biological: Intravenous injection of EBV specific CTLs Each patient will receive injections of 2x10e7 , |
Active, not recruiting |
Study Name: Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy Condition:
Date: 2010-03-26 Interventions: Biological: Recombinant Epstein-Barr Virus (EBV) Vaccine |